We further provide evidence that pharmacological and genetic ablation of these molecules in mice reverses the adverse renal effects of obesity; therefore, an intervention targeting the HA-CD44/RHAMM pathway may represent a novel therapeutic strategy against the progression of obesity-induced kidney injury. The gene discussed is CD44; the disease is obesity due to melanocortin 4 receptor deficiency.